$1.24
+0.21 (+20.39%)
Open$1.15
Previous Close$1.03
Day High$1.36
Day Low$1.05
52W High$209.50
52W Low—
Volume—
Avg Volume3.98M
Market Cap3.99M
P/E Ratio—
EPS$-200.08
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+194.4% upside
Current
$1.24
$1.24
Target
$3.65
$3.65
$2.40
$3.65 avg
$4.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 152.21M | 335.8K | 347.3K |
| Net Income | -2,619,512,706 | 43.0K | 52.4K |
| Profit Margin | -1,721.0% | 12.8% | 15.1% |
| EBITDA | -4,372,465,787 | 73.2K | 78.8K |
| Free Cash Flow | — | 45.7K | 64.8K |
| Rev Growth | — | +0.6% | +12.6% |
| Debt/Equity | — | 0.59 | 0.52 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |